Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

The U.S.-listed shares of Cellectis S.A.

rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZeneca PLC AZN, +0.46% as part of a collaboration agreement that leverages Cellectis’ gene editing technologies. Trading volume ballooned to 10.8 million shares, compared with the full-day average of about 68,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges ahead of the open.

ایران آخرین اخبار, ایران سرفصلها

Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.

Revvity’s stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlookTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
منبع: MarketWatch - 🏆 3. / 97 ادامه مطلب »